Press release
Dermatology Drugs Market By Growth Factors and Key Players: Allergan Plc, Valeant Pharmaceuticals, Dermira Inc, Aclaris Therapeutics, Inc, AnaptysBio, Inc, Revance Therapeutics, Foamix Pharmaceuticals, Novan, Inc, Sienna Biopharmaceuticals
Dermatology Drugs Market
“Dermatology Drugs Market by Therapeutic Area Segments (Atopic Dermatitis, Psoriasis, Acne, Rosacea), Acne Drug Types (Doxycycline, Absorica, Clindamycin, Myorisan, Aczone, Epiduo) Marketed Therapies (Biologics, Oral Drugs, Topical Drugs), by Approves Treatments (Etanercept (Enbrel), Infliximab (Remicade), Adalimumab (Humira), Ustekinumab (Stelara), Secukinumab (Cosentyx), Ixekizumab (Taltz), Golimumab (Simponi), Brodalumab (Siliq), Guselkamab (Tremfya) and Others) and by Regions (North America, Europe, Asia Pacific, Latin America and Middle East & Africa) - Global Forecasts to 2022"- a Report by Polaris Market Research
Request for a sample of this research report @ https://www.polarismarketresearch.com/industry-analysis/dermatology-drugs-market/request-for-free-sample
The Global Dermatology drugs market was valued at USD 21.32 billion in 2017 as reported by Polaris Market Research. The market is primed to exhibit strong commercial opportunity driven by psoriasis, atopic dermatitis, and aesthetic dermatology indications. The market expansion in dermatology is fueled by the addition of improved formulations of approved treatments in acne and rosacea and the approval of several biologics in psoriasis in recent times. The dermatology is a large but fragmented market opportunity and there remains the significant unmet need for safer and cost-effective treatment options.
The psoriasis market remains the largest and the most promising segment within the broader dermatology category. The psoriasis market is poised to increase from USD 4.08 billion in 2017 to over USD 4.86 billion in 2022 driven by increased penetration of anti-TNFs and the recent market launch of a wave of next-generation biologics led by interleukin (IL-17) class.
There remains significant unmet need to treat moderate to severe atopic dermatitis due to limited effective and long-term therapeutic options. Acne infected population is substantially large and Polaris estimates the market to reach USD 8.47 billion by 2022. Atopic Dermatitis was the largest therapeutic area segment in 2017. And, Polaris estimates that this segment is projected to increase at a CAGR of 3.9% from 2018 to 2022.
Browse Complete Summary of this report @ https://www.polarismarketresearch.com/industry-analysis/dermatology-drugs-market/
Polaris Market Research estimates the acne at over USD 6.8 billion in 2017. The key prescription treatments for acne include topical retinoids, topical and oral antimicrobials, and oral isotretinoin. The non-prescription market for acne is more attractive commercially and is expected to almost double the size of the prescription market by 2022. Topical therapies dominate acne treatment and hold the majority of the market share. Several promising drugs are currently in clinical development in the treatment of acne. Key among them includes Foamix’s FMX-101, the first topical minocycline that demonstrated positive results in the Phase III study. Dermira’s DRM01 remains the first topical sebum inhibitor which demonstrated improved efficacy in Phase II trials. The Phase III study results in adult and adolescent acne patients are expected to read out in 2018.
Geographically, the U.S. remained the single largest market followed by Europe and Japan. The largest market size of the U.S. is attributable to rising adoption of high-priced biologics. The penetration of biologics in the U.S. for dermatological indication especially in psoriasis is still below 10% and the market continues to remain underpenetrated.
Polaris Market Research has modelled forecast market sales of Dermatology drugs from 2016-2022. The key therapeutic segments which have been investigated in the global market from 2016-2022 are:
• Market Analysis by Key Therapeutic Indications
• Market Analysis by Leading and Emerging Approved Treatment Types
• Market Analysis by Marketed Drugs
• Market Analysis by Geographic Regions
Make Inquiry about this report @ https://www.polarismarketresearch.com/industry-analysis/dermatology-drugs-market/inquire-before-buying
Leading Companies investigated in the Report are:
1. Allergan Plc
2. Valeant Pharmaceuticals
3. Dermira Inc
4. Aclaris Therapeutics, Inc
5. AnaptysBio, Inc
6. Revance Therapeutics
7. Foamix Pharmaceuticals
8. Novan, Inc
9. Sienna Biopharmaceuticals
10. Pfizer
11. Sanofi
12. Galderma
13. Leo Pharma
14. Roviant Sciences
15. Otsuka Pharmaceuticals
Key Segments
Therapeutic Area Segments
• Atopic Dermatitis
• Psoriasis
• Acne
• Rosacea
Acne Drug Segments
• Doxycycline
• Absorica
• Clindamycin
• Myorisan
• Aczone
• Epiduo
Marketed Therapies Segments
• Biologics
• Oral Drugs
• Topical Drugs
Approved Treatments Segments
• Etanercept (Enbrel)
• Infliximab (Remicade)
• Adalimumab (Humira)
• Ustekinumab (Stelara)
• Secukinumab (Cosentyx)
• Lxekizumab (Taltz)
• Golimumab (Simponi)
• Brodalumab (Siliq)
• Guselkamab (Tremfya)
• Others
Get customization report @ https://www.polarismarketresearch.com/industry-analysis/dermatology-drugs-market/request-for-customization
About Polaris Market Research
Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for our clientele spread across different enterprises. We at Polaris are obliged to serve our diverse customer base present across the industries of healthcare, technology, semi-conductors and chemicals among various other industries present around the world. We strive to provide our customers with updated information on innovative technologies, high growth markets, emerging business environments and latest business-centric applications, thereby helping them always to make informed decisions and leverage new opportunities. Adept with a highly competent, experienced and extremely qualified team of experts comprising SMEs, analysts and consultants, we at Polaris endeavor to deliver value-added business solutions to our customers.
Contact us
Mr. Neel
Corporate Sales, USA
Polaris Market Research
Phone: 1-646-568-9980
Email: neel@polarismarketresearch.com
Web: www.polarismarketresearch.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Dermatology Drugs Market By Growth Factors and Key Players: Allergan Plc, Valeant Pharmaceuticals, Dermira Inc, Aclaris Therapeutics, Inc, AnaptysBio, Inc, Revance Therapeutics, Foamix Pharmaceuticals, Novan, Inc, Sienna Biopharmaceuticals here
News-ID: 1341691 • Views: …
More Releases from Polaris Market Research & Consulting
Last Mile Delivery Market Valued US$ 297.57 Billion and Expected to Register 8.6 …
According to Polaris Market Research's latest study, "Last Mile Delivery Market by Service Type (B2C, B2B, C2C); Technology (Autonomous, Non-Autonomous); Application; Region, And Segment Forecasts, 2024 - 2032," the market for last mile delivery was valued at USD 142.21 billion in 2023. It is anticipated to grow to USD 297.57 billion by 2032 and exhibit a compound annual growth rate of 8.60% during the forecast period from 2024 to 2032.
𝐄𝐱𝐩𝐥𝐨𝐫𝐞…
Terminal Tractor Market Valued US$ 1,245.08 Million and Expected to Register 4.6 …
Polaris Market Research has added the latest Report on the Terminal Tractor Market. The report primarily includes share, size, demand, growth factors, revenue, and analysis of global companies. The global market was valued at USD 835.67 Million in 2023 and is expected to grow to USD 1,245.08 Million by 2032 at a CAGR of 4.60% during the forecast period.
𝐄𝐱𝐩𝐥𝐨𝐫𝐞 𝐅𝐫𝐞𝐞 𝐒𝐚𝐦𝐩𝐥𝐞 𝐏𝐃𝐅 𝐑𝐞𝐩𝐨𝐫𝐭: https://www.polarismarketresearch.com/industry-analysis/terminal-tractor-market/request-for-sample
𝐌𝐚𝐫𝐤𝐞𝐭 𝐈𝐧𝐭𝐫𝐨𝐝𝐮𝐜𝐭𝐢𝐨𝐧
A terminal tractor, sometimes called…
Coronary Stent Market is expected to reach US$ 12,248.80 Million by 2032, at a C …
According to Polaris Market Research's study, the Coronary Stent Market is expected to grow at a CAGR of 4.40% over the estimated period. The industry value is expected to grow from USD 8306.55 million in 2023 to USD 12,248.80 million in 2032.
The industry's growth is being fuelled by the growing pervasiveness of coronary heart disorders globally. Also, the market for coronary stents is expanding because clinical trials are being…
Public Key Infrastructure (PKI) Market Sets New Record, Projected at USD 19657.5 …
The public key infrastructure (PKI) market size is projected to be valued at USD 3032.9 million in 2023 and is expected to rise to USD 19657.5 million by 2032. The market is expected to register a CAGR of 20.6% during the forecast period. Various factors propelling the demand for PKI include:
● The public key infrastructure (PKI) industry is expanding due to notable innovation in the business and corporate sectors, which supports…
More Releases for Drug
Alcohol Testing And Drug Testing Equipment Market 2025 Segmentation, Application …
Market Study Report, LLC, has compiled an exhaustive research study of the ‘Alcohol Testing And Drug Testing Equipment market’, detailing every single market driver and intricately analyzing the business vertical. This ‘Alcohol Testing And Drug Testing Equipment market’ study will aid in seeking out new business opportunities and fine-tuning existing marketing strategies through insights regarding SWOT analysis, market valuation, competitive spectrum, regional share, and revenue predictions.
Alcohol abuse and drug…
How much Diabetes Drug Market Impact Worldwide Medical Drug Industry?
Diabetes Drug Market From an insight perspective, the market report focuses on various levels of analyses — industry analysis, market rank analysis, and company profiles, which together comprise and discuss basic views on the competitive landscape, high-growth regions, and countries as well as their respective regulatory policies, Types ,Applications and opportunities in the market.
Diabetes is a metabolic disorder in which the body glucose level is elevated. There are two types of diabetes…
Hepatitis Drug Market Hepatitis Drug Clinical Pipeline Report 2023
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990
Report Table of Contents
1. Introduction to Hepatitis Disease
1.1 Prologue
1.1.1 History of Hepatitis
1.1.2 Causes of Hepatitis Disease
1.2 Types of Viruses which are Responsible for Hepatitis Disease
2. Global Prevalence of Hepatitis Infection
3. Available Drug Classes for Hepatitis Disease Treatment
3.1 Interferon Alfa Therapy
3.2 Protease Inhibitors Therapy
3.3 Polymerase…
Microcapsules Drug Delivery Market Microcapsules Drug Delivery Sales Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990
Report Table of Contents
1. Indispensable Advent of Microcapsules
1.1 Trajectory of Microencapsulation
1.2 Why and wherefores for Microencapsulation
2. Characterization of Microcapsules
2.1 Composition of Microcapsules
2.2 Parameters Influencing Microcapsules
3. Engineering Technology of Microcapsules
3.1 Physical Manufacturing Technologies
3.2 Physicochemical and Chemical Technologies
4. Applicability of Microcapsules
4.1 Microcapsules in Pharmaceuticals
4.2 Microcapsules in Nutraceuticals
…
AstraZeneca’s NMOSD Drug receives orphan drug designation
April 18, 2017 Orphan Drug
European Medicine Agency has Announced orphan drug designation for inebilizumab (earlier known as MEDI-551) developed by AstraZeneca PLC (AZN) for the treatment of neuromyelitis optica spectrum disorder (NMOSD). The drug has already received orphan drug status from US Food and Drug Administration (FDA). NMOSD, also called Devic’s disease, is a rare, autoimmune disorder of the central nervous system (CNS) that affects the functioning…
Drug Discovery Strategies, PBPK Modeling and Drug-Drug Interaction Explored and …
This year’s 12th annual ADMET conference and exhibition promises to deliver appearances from experienced pharmaceutical professionals from ADME and PK/PD organisations such as AbbVie, GSK, Roche and Bayer when it returns to London this June.
The carefully selected speaker line up will be addressing early ADME application strategies and discussing the latest technologically advanced screening and testing models along with exploring ADMET technologies which will identify properties of a drug…
